Blood Consensus Maps Pediatric AML From Diagnosis To Supportive Care

A pediatric AML consensus report summarizes panel guidance across diagnosis, risk determination (including genetic testing), response criteria, therapy selection, relapse management considerations, and supportive care for children, adolescents, and young adults. The panel distinguishes pediatric disease from adult AML by emphasizing distinct cytogenetic and molecular patterns, pediatric response criteria, and age-specific supportive measures. Taken together, the report keeps core diagnostic and management domains in view from presentation through follow-up.

At presentation, the report describes a marrow-centered diagnostic approach using morphology, flow cytometry immunophenotyping, comprehensive genetic testing, and central nervous system staging with cerebrospinal fluid analysis via lumbar puncture, with antecedent CNS imaging when focal neurologic findings or signs of raised intracranial pressure are present.

Peripheral blood can support rapid diagnostics when circulating blasts are present or when instability limits anesthesia or other invasive procedures. The testing strategy combines karyotyping with FISH, PCR-based assays, and sequencing methods, and it also considers HLA typing at diagnosis for transplant planning. Alongside marrow acquisition, blood-based contingencies, and CNS evaluation, the initial diagnostic and staging workup is presented as a unified starting point.

The authors organize pediatric AML classification around recurrent genetic alterations that define biologic subtypes more precisely than older morphology-based schemes alone. They highlight groups such as KMT2A-rearranged disease, core-binding factor leukemias with RUNX1::RUNX1T1 or CBFB::MYH11, acute promyelocytic leukemia with PML::RARA, and NUP98-rearranged AML. Risk assignment then combines these genetic findings with early induction response, and the panel notes that some subgroups are consistently favorable or high risk. This approach presents leukemia biology and early treatment response together in pediatric risk assignment.

For response assessment, the panel identifies multiparameter flow cytometry as the preferred method for measurable residual disease detection after intensive therapy. Morphology remains complementary, but the authors note that flow cytometry better separates residual leukemia from regenerating marrow and supports sensitive pediatric monitoring. They also propose pediatric remission categories that include CR, CRp, and CRi, alongside MRD-negative complete remission as a key response designation. These elements form the report’s framework for how remission is measured, interpreted, and categorized.

Across newly diagnosed and relapsed disease, the panel outlines risk-adapted multiagent chemotherapy, targeted agents for selected subgroups, and allogeneic HSCT according to risk, remission status, and relapse. The authors also address pediatric-specific settings including APL, germ line predisposition syndromes, myeloid neoplasms after prior cytotoxic therapy, and myeloid leukemia of Down syndrome. Supportive care spans anti-infective prophylaxis, cardiac surveillance, transfusion support, tumor lysis precautions at presentation, and survivorship follow-up after therapy completion. Treatment planning and supportive care are described as parallel, coordinated parts of pediatric AML management.

Key Takeaways

• The panel describes pediatric AML diagnosis as a multimodal process tied to marrow studies, genetics, and staging.
• Genetic findings and early response, including flow cytometry MRD, are described as inputs used in classification and risk assessment.
• Risk-adapted therapy, relapse planning, and supportive care are described together within the pediatric AML framework.